Navigation Links
Laureate Announces Manufacturing Agreement with Tolerx
Date:10/21/2008

-Laureate to Manufacture Tolerx's TRX518 Antibody

PRINCETON, N.J., Oct. 21 /PRNewswire/ -- Laureate Pharma, Inc., a full- service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases. Under the agreement, Laureate will produce Tolerx's humanized anti-GITR antibody known as TRX518, which is currently in development for cancer and chronic viral indications. Details of the agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO)

"The partnership with Tolerx validates the progress we have made in biomanufacturing and our commitment in helping our clients bring novel therapies to the market," said Robert J. Broeze, Ph.D., President & Chief Executive Officer of Laureate. "With our well established monoclonal antibody experience, we will partner closely with the Tolerx team to help them achieve their manufacturing objectives."

"Laureate Pharma has a proven track record in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials," said Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx. "This agreement enables us to operationally leverage Laureate's expertise and infrastructure while we seek to establish new treatment paradigms in the immunology space."

About Laureate Pharma, Inc.

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com.

About Tolerx

Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. TRX518 is directed to GITR and is in preclinical development for the treatment of cancer and chronic viral diseases. TRX518 is thought to circumvent immune system tolerance by inhibiting the suppressive activity of T regulatory cells and extending the survival of T effector cells, thereby enhancing responses to tumor and viral antigens. Tolerx also has two antibodies in clinical development for the treatment of various autoimmune indications, these are: otelixizumab, an anti-CD3 MAb that is being developed in collaboration with GlaxoSmithKline and MTRX1011A a modified form of TRX1, an anti-CD4 MAb that is being developed in collaboration with Genentech, Inc. In addition to TRX518, Tolerx is also engaged in the preclinical development of other antibodies that may shift or modulate the immune system. For more information, please visit http://www.tolerx.com.


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
2. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
5. Laureate Pharma Appoints Gary Swan as Vice President of Operations
6. Laureate Pharma Reports Record Growth for 2007
7. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
8. ARUP Laboratories ARUP Consult(R) Recognized as a Computerworld Honors Program Laureate
9. Laureate Pharma to Add More Manufacturing Capacity
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... for North American hospitals, will present its chain-of-custody solution for tracking and securing ... Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven solution for ...
(Date:12/2/2016)... IL (PRWEB) , ... December 01, 2016 , ... ... to congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance ... cleared a significant hurdle in commercializing remote cardiac monitoring devices that rely on ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... ALBANY, New York , November 30, 2016 /PRNewswire/ ... exceptionally consolidated as a few players hold a dominant ... Lonza Group, Charles River Laboratories International, Inc., and Merck ... global market in 2015. Transparency Market Research observes that ... they are focused on development products that are do ...
Breaking Biology Technology:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
Breaking Biology News(10 mins):